TrueD application for assessing therapy response in oncologic patients

1299 Learning Objectives 1. To know the future usefulness of three-dimensional(3-D) displays for medical imaging for therapeutic response monitoring and detection of tumor recurrence. 2. To assess morphological criteria for defining therapy response(CR, PR, SD, PD) established with RECIST(Response evaluation criteria in solid tumors) with the adoption of metabolic imaging with PET/CT. Three-dimensional(3-D) displays for medical imaging iare now emerging field and very promising tools for diagnosis, therapeutic response monitoring and detection of tumor recurrence. Morphological criteria for defining therapy response(CR, PR, SD, PD) have been established with RECIST(Response evaluation criteria in solid tumors). With the adoption of metabolic imaging with PET/CT, particularly with F-18-FDG in initial staging and follow up of various cancers, there appears to be a need to modify these criteria not only on morphological imaging modalities like CT, but also on tumor metabolism parameters, like SUV(standardized uptake value) as measured by PET. Furthermore, 3-D imaging taken from PET/CT can be an excellent approach to assess the tumor response after appropriate therapy. In this poster presentation, we will discuss the TrueD(Siemens) application of F-18-FDG PET/CT for both initial staging and post-therapeutic follow-up in various oncologic patients. Among many galleries, the most optimal palette will be recommended according to anatomic location of the primary tumor and various characteristics. The recent development of three- and four-dimensional image processing will lead medical imaging to full definition volumetric display for clinician as well as patients themselves. VOIs(volume of interests) of 2 or 3 time points display can be saved and exported as a powerful and comprehensive images through the any PACS systems.